Validation of the Partin Nomogram for Prostate Cancer in a National Sample

被引:49
|
作者
Yu, James B. [1 ]
Makarov, Danil V. [3 ,5 ]
Sharma, Richa [4 ]
Peschel, Richard E. [1 ]
Partin, Alan W. [6 ]
Gross, Cary P. [2 ,3 ]
机构
[1] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA
[3] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06520 USA
[4] Yale Univ, Sch Med, Sch Epidemiol & Publ Hlth, New Haven, CT 06520 USA
[5] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA
[6] Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA
关键词
prostate; prostatic neoplasms; neoplasm staging; nomograms; SEER program; PREDICT PATHOLOGICAL STAGE; RADICAL PROSTATECTOMY; CLINICAL STAGE; GLEASON SCORE; EXTERNAL VALIDATION; RADIATION-THERAPY; TABLES; ANTIGEN; MEN; ADENOCARCINOMA;
D O I
10.1016/j.juro.2009.08.143
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The Partin tables are a nomogram that is widely used to discriminate prostate cancer pathological stages, given common preoperative clinical characteristics. The nomogram is based on patients undergoing radical prostatectomy at The Johns Hopkins Medical Institutions. We validated the Partin tables in a large, population based sample. Materials and Methods: The National Cancer Institute Surveillance, Epidemiology and End Results database was used to identify patients treated from 2004 to 2005 who underwent radical prostatectomy. The 2007 Partin tables were used to estimate the prevalence of positive lymph nodes, seminal vesicle invasion, extraprostatic extension and organ confined disease in men with prostate cancer in the database using clinical stage, preoperative prostate specific antigen and Gleason score. The discriminative ability of the tables was explored by constructing ROC curves. Results: We identified 11,185 men who underwent radical prostatectomy for prostate cancer in 2004 to 2005. The Partin tables discriminated well between patient groups at risk for positive lymph nodes and seminal vesicle invasion (AUC 0.77 and 0.74, respectively). The discrimination of extraprostatic extension and organ confined disease was more limited (AUC 0.62 and 0.68, respectively). The AUC for positive lymph nodes was 0.78 in white men, 0.73 in black men and 0.83 in Asian/Pacific Islander men (p = 0.17). The AUC for positive lymph nodes in men 61 years old or younger was 0.80 vs 0.74 in men older than 61 years (p 0.03). Conclusions: The Partin tables showed excellent discrimination for seminal vesicle invasion and positive lymph nodes. Discrimination of extraprostatic extension and organ confined disease was more limited. The Partin tables performed best in young men.
引用
收藏
页码:105 / 111
页数:7
相关论文
共 50 条
  • [31] External validation of Cormio nomogram for predicting all prostate cancers and clinically significant prostate cancers
    Cindolo, Luca
    Bertolo, Riccardo
    Minervini, Andrea
    Sessa, Francesco
    Muto, Gianluca
    Bove, Pierluigi
    Vittori, Matteo
    Bozzini, Giorgio
    Castellan, Pietro
    Mugavero, Filippo
    Falsaperla, Mario
    Schips, Luigi
    Celia, Antonio
    Bada, Maida
    Porreca, Angelo
    Pastore, Antonio
    Al Salhi, Yazan
    Giampaoli, Marco
    Novella, Giovanni
    Rizzetto, Riccardo
    Trabacchin, Nicolo
    Mantica, Guglielmo
    Pini, Giovannalberto
    Lombardo, Riccardo
    Tubaro, Andrea
    Antonelli, Alessandro
    De Nunzio, Cosimo
    WORLD JOURNAL OF UROLOGY, 2020, 38 (10) : 2555 - 2561
  • [32] Validation of an MRI-based prostate cancer prebiopsy Gleason score predictive nomogram
    Lee, Adrianna Jiaying
    Wnorowski, Amelia
    Ye, Nancy
    Xu, Linhan
    Naslund, Michael
    Wood, Bradford J.
    Merino, Maria J.
    Turkbey, Baris
    Choyke, Peter L.
    Pinto, Peter A.
    Siddiqui, M. Minhaj
    CURRENT UROLOGY, 2022, 16 (01) : 38 - 43
  • [33] Assessing the clinical benefit of a nomogram to predict specimen-confined disease at radical prostatectomy in patients with high-risk prostate cancer: An external validation
    Hansen, Jens
    Becker, Andreas
    Kluth, Luis A.
    Rink, Michael
    Steuber, Thomas
    Zacharias, Mario
    Briganti, Alberto
    Fisch, Margit
    Graefen, Markus
    Chun, Felix K. -H.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (09) : 384.e1 - 384.e8
  • [34] National Trends in the Management of Low and Intermediate Risk Prostate Cancer in the United States
    Weiner, Adam B.
    Patel, Sanjay G.
    Etzioni, Ruth
    Eggener, Scott E.
    JOURNAL OF UROLOGY, 2015, 193 (01) : 95 - 102
  • [35] A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling
    Moussa, Ayman S.
    Kattan, Michael W.
    Berglund, Ryan
    Yu, Changhong
    Fareed, Khaled
    Jones, J. Stephen
    BJU INTERNATIONAL, 2010, 105 (03) : 352 - 358
  • [36] Prostate Cancer Detection Rate in Patients with Repeated Extended 21-Sample Needle Biopsy
    Campos-Fernandes, Jean-Louis
    Bastien, Laurence
    Nicolaiew, Nathalie
    Robert, Gregoire
    Terry, Stephane
    Vacherot, Francis
    Salomon, Laurent
    Allory, Yves
    Vordos, Dimitri
    Hoznek, Andras
    Yiou, Rene
    Patard, Jean Jacques
    Abbou, Claude Clement
    de la Taille, Alexandre
    EUROPEAN UROLOGY, 2009, 55 (03) : 600 - 609
  • [37] The importance of tumor palpability and transrectal ultrasonographic appearance in the contemporary clinical staging of prostate cancer
    Eisenberg, Michael L.
    Cowan, Janet E.
    Davies, Benjamin J.
    Carroll, Peter R.
    Shinohara, Katsuto
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (02) : 171 - 176
  • [38] External validation of a PCA-3-based nomogram for predicting prostate cancer and high-grade cancer on initial prostate biopsy
    Greene, Daniel J.
    Elshafei, Ahmed
    Nyame, Yaw A.
    Kara, Onder
    Malkoc, Ercan
    Gao, Tianming
    Jones, J. Stephen
    PROSTATE, 2016, 76 (11) : 1019 - 1023
  • [39] External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients
    Beauval, Jean-Baptiste
    Cabarrou, Bastien
    Gandaglia, Giorgio
    Patard, Pierre-Marie
    Ouzzane, Adil
    de la Taille, Alexandre
    Soulie, Michel
    Briganti, Alberto
    Ploussard, Guillaume
    Rozet, Francois
    Roumiguie, Mathieu
    PROSTATE, 2017, 77 (08) : 928 - 933
  • [40] A novel nomogram to predict the probability of prostate cancer on repeat biopsy
    Benecchi, Luigi
    Pieri, Anna Maria
    Melissari, Massimo
    Potenzoni, Michele
    Pastizzaro, Carmelo Destro
    JOURNAL OF UROLOGY, 2008, 180 (01) : 146 - 149